尾加压素Ⅱ在支气管哮喘中病理生理作用的研究进展  

Research Progresses in Pathophysiological Roles of Urotensin Ⅱ in Plasma of Bronchial Asthma Patients

作　　者：王超[1] 李淑兰[1] 

机构地区：[1]潍坊医学院内科学教研室

出　　处：《医学综述》2009年第3期423-425,共3页Medical Recapitulate

摘　　要：支气管哮喘是呼吸系统的常见疾病之一，是由多种细胞和细胞组分参与的气道慢性炎症性疾病，其发病机制不完全清楚，随着哮喘病理生理和不同炎症表型的知识不断增加，多种因素参与其发病过程的理论也在逐渐被实践证实。其中尾加压素Ⅱ就可能是参与支气管哮喘的发病过程并发挥重要生物学效应的因素之一。本文就尾加压素Ⅱ在支气管哮喘病理生理中的作用予以简要综述。As one of the common disease in respiratory system, bronchial asthma is the chronic airway inflammatory disease which involved by a variety of cells and cell components. Its pathogenesis is not entirely clear. With the increasing knowledge about pathophysiology and inflammatory phenotype of asthma, the theory that a number of factors involved in the pathogenesis of asthma is also gradually being confirmed in practice. Urotensin Ⅱ may be one of the factors which involved in the pathogenesis of asthma and play an important biological effect. This article reviewed the effects of urotensin Ⅱ on pathophysiologic effects of bronchial asthma in brief.

关 键 词：尾加压素Ⅱ 支气管哮喘 病理生理学 

分 类 号：R562.25[医药卫生—呼吸系统]